Company Filing History:
Years Active: 1984
Title: Akira Fukui: Innovator in Pharmaceutical Chemistry
Introduction
Akira Fukui is a notable inventor hailing from Kasugai, Japan, recognized for his contributions to the field of pharmaceutical chemistry. With a keen focus on novel compounds, Fukui has made significant advancements in the development of CNS-active pharmaceutical agents. His inventive spirit is demonstrated through his patented work that showcases unique chemical derivatives aimed at enhancing therapeutic outcomes.
Latest Patents
Fukui holds a patent for "2,5-Benzodiazocine derivatives and salts thereof." This invention includes a specific 2,5-benzodiazocine derivative represented by a formula where R₁ is either phenyl or p-methoxyphenyl, R₂ is hydrogen or methyl, and R₃ encompasses various chemical groups such as p-methoxyphenethyl, 3-(p-fluorobenzoyl)-propyl, cyclopropylmethyl, or derivatives of these components. The patent also describes a CNS-active pharmaceutical agent containing at least one of these innovative derivatives and their corresponding salts.
Career Highlights
Fukui has built a distinguished career within Sanwa Kagaku Kenkyusho Co., Ltd., a prominent organization in the pharmaceutical and chemical research fields. His work within this company has contributed significantly to the development of new medications and treatments that could potentially address various neurological conditions.
Collaborations
Throughout his career, Akira Fukui has collaborated with esteemed colleagues such as Masatoshi Ban and Kenji Miura. Their combined efforts reflect a strong team dynamic, fostering innovation and the successful development of new pharmaceutical solutions.
Conclusion
In summary, Akira Fukui stands out as a remarkable inventor who has made pivotal contributions to pharmaceutical chemistry through his patented work. His collaborations and career at Sanwa Kagaku Kenkyusho Co., Ltd. exemplify his dedication to advancing medical science and improving health outcomes. The impact of his inventions continues to be felt in the industry, as they pave the way for new therapeutic possibilities.